Literature DB >> 28515248

Systemic Management of Colorectal Cancer.

Wells A Messersmith1.   

Abstract

Advances have been made in the systemic treatment of colorectal cancer, with approximately 12 chemotherapy or biologic agents approved for use as a single agent or in a combination. However, numerous gaps in our understanding of the disease remain, such as the lack of benefit with biologics in the adjuvant setting, the absence of biomarkers for most systemic therapies, and the reason why left-sided and right-sided tumors behave differently. At the 22nd NCCN Annual Conference, Dr. Wells A. Messersmith presented several impactful updates to the 2017 NCCN Clinical Practice Guidelines in Oncology for Colon Cancer and reviewed the outcomes with a host of therapies used for both early-stage and metastatic disease.
Copyright © 2017 by the National Comprehensive Cancer Network.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28515248     DOI: 10.6004/jnccn.2017.0077

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  9 in total

1.  Failure to administer recommended chemotherapy: acceptable variation or cancer care quality blind spot?

Authors:  Ryan J Ellis; Cary Jo R Schlick; Joe Feinglass; Mary F Mulcahy; Al B Benson; Sheetal M Kircher; Tony D Yang; David D Odell; Karl Bilimoria; Ryan P Merkow
Journal:  BMJ Qual Saf       Date:  2019-07-31       Impact factor: 7.035

Review 2.  Colorectal Cancer: Why Does Side Matter?

Authors:  Claire Gallois; Simon Pernot; Aziz Zaanan; Julien Taieb
Journal:  Drugs       Date:  2018-06       Impact factor: 9.546

3.  Inhibition of Angiogenesis and Extracellular Matrix Remodeling: Synergistic Effect of Renin-Angiotensin System Inhibitors and Bevacizumab.

Authors:  Tianshu Ren; Hui Jia; Qiong Wu; Yan Zhang; Qun Ma; Dong Yao; Xudong Gao; Danni Xie; Zihua Xu; Qingchun Zhao; Yingshi Zhang
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

4.  Efficacy and Safety of Bevacizumab Plus Oxaliplatin- or Irinotecan-Based Doublet Backbone Chemotherapy as the First-Line Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis.

Authors:  Tianshu Ren; Shu Wang; Zexu Shen; Chang Xu; Yingshi Zhang; Fuhai Hui; Xingshun Qi; Qingchun Zhao
Journal:  Drug Saf       Date:  2020-11-12       Impact factor: 5.606

5.  Differences between carcinoma of the cecum and ascending colon: Evidence based on clinical and embryological data.

Authors:  Xin Xie; Zhangjian Zhou; Yongchun Song; Wei Wang; Chengxue Dang; Hao Zhang
Journal:  Int J Oncol       Date:  2018-04-12       Impact factor: 5.650

6.  Synchronous isolated splenic metastasis from cancer of hepatic flexure of colon: A case report.

Authors:  Huiying Zhao; Weixiang Zhong; Dong Chen; Xiaofei Cheng
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

7.  hERG1 and HIF-2α Behave as Biomarkers of Positive Response to Bevacizumab in Metastatic Colorectal Cancer Patients.

Authors:  Jessica Iorio; Elena Lastraioli; Lorenzo Tofani; Giulia Petroni; Lorenzo Antonuzzo; Luca Messerini; Giuseppe Perrone; Damiano Caputo; Maria Francesconi; Maria Michelina Amato; Moris Cadei; Giuseppina Arcangeli; Vincenzo Villanacci; Luca Boni; Roberto Coppola; Francesco Di Costanzo; Annarosa Arcangeli
Journal:  Transl Oncol       Date:  2020-02-25       Impact factor: 4.243

8.  E3 ubiquitin ligase MAGI3 degrades c-Myc and acts as a predictor for chemotherapy response in colorectal cancer.

Authors:  Haibo Wang; Wenjing Yang; Qiong Qin; Xiaomei Yang; Ying Yang; Hua Liu; Wenxiu Lu; Siyu Gu; Xuedi Cao; Duiping Feng; Zhongtao Zhang; Junqi He
Journal:  Mol Cancer       Date:  2022-07-22       Impact factor: 41.444

9.  The Effect of Compound Sophora on Fluorouracil and Oxaliplatin Resistance in Colorectal Cancer Cells.

Authors:  WeiHua Yin; GuPing Zhong; HuiZhen Fan; HongMei Xia
Journal:  Evid Based Complement Alternat Med       Date:  2019-12-27       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.